157 related articles for article (PubMed ID: 38151961)
21. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
[TBL] [Abstract][Full Text] [Related]
22. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U; Fehr M; Schär S; Dreyling M; Schmidt C; Derenzini E; Zander T; Hess G; Mey U; Ferrero S; Mach N; Boccomini C; Böttcher S; Voegeli M; Cairoli A; Ivanova VS; Menter T; Dirnhofer S; Scheibe B; Gadient S; Eckhardt K; Zucca E; Driessen C; Renner C
EClinicalMedicine; 2023 Oct; 64():102221. PubMed ID: 37781158
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Obr A; Benesova K; Janikova A; Mocikova H; Belada D; Hruskova A; Vockova P; Salek D; Sykorova A; Furst T; Malarikova D; Papajik T; Trneny M; Klener P
Ann Hematol; 2023 Jan; 102(1):107-115. PubMed ID: 36369497
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
27. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A; Shotton R; Eyre TA; Lewis D; Stanton L; Allchin R; Walter H; Miall F; Zhao R; Santarsieri A; McCulloch R; Bishton M; Beech A; Willimott V; Fowler N; Bedford C; Goddard J; Protheroe S; Everden A; Tucker D; Wright J; Dukka V; Reeve M; Paneesha S; Prahladan M; Hodson A; Qureshi I; Koppana M; Owen M; Ediriwickrema K; Marr H; Wilson J; Lambert J; Wrench D; Burney C; Knott C; Talbot G; Gibb A; Lord A; Jackson B; Stern S; Sutton T; Webb A; Wilson M; Thomas N; Norman J; Davies E; Lowry L; Maddox J; Phillips N; Crosbie N; Flont M; Nga E; Virchis A; Camacho RG; Swe W; Pillai A; Rees C; Bailey J; Jones S; Smith S; Sharpley F; Hildyard C; Mohamedbhai S; Nicholson T; Moule S; Chaturvedi A; Linton K
Blood Adv; 2024 Mar; 8(5):1209-1219. PubMed ID: 38127279
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
31. The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
Tucker D; Morley N; MacLean P; Vandenberghe E; Booth S; Parisi L; Rule S
Br J Haematol; 2021 Mar; 192(6):1035-1038. PubMed ID: 32445482
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Agarwal MB; Bhurani D; Shah C; Sood N; Singhal M; Kamat A; Chezhian S; Mishra S; Nagrale D
Indian J Med Paediatr Oncol; 2017; 38(4):508-515. PubMed ID: 29333021
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Stefoni V; Pellegrini C; Broccoli A; Baldini L; Tani M; Cencini E; Figuera A; Ansuinelli M; Bernocco E; Cantonetti M; Cox MC; Ballerini F; Rusconi C; Visco C; Arcaini L; Fama A; Marasca R; Volpetti S; Castellino A; Califano C; Cavaliere M; Gini G; Liberati AM; Musuraca G; Lucania A; Ricciuti G; Argnani L; Zinzani PL
Oncologist; 2018 Sep; 23(9):1033-1038. PubMed ID: 29674440
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
36. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review.
Sancho JM; Sorigué M; Rubio-Azpeitia E
J Blood Med; 2024; 15():239-254. PubMed ID: 38812568
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract][Full Text] [Related]
39. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
40. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
